GLOW 70mg

What is GLOW ?

GLOW is one pre-blended vial holding BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg: 70mg of lyophilised powder in total. One reconstitution puts all three into solution. The powder is blue, from the copper in GHK-Cu.

BPC-157 is the 15-residue pentadecapeptide GEPPPGKPADDAGLV (1419.53 g/mol, CAS 137525-51-0). TB-500 is synthetic thymosin beta 4, 43 residues (4963.4 g/mol, CAS 77591-33-4). GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine (403.9 g/mol, CAS 89030-95-5).

GLOW is a supplier designation for a pre-blended multi-peptide research vial, not a single chemical entity. The GLOW 70mg vial contains BPC-157 10mg (pentadecapeptide GEPPPGKPADDAGLV, C₆₂H₉₈N₁₆O₂₂, 1419.53 g/mol, CAS 137525-51-0), TB-500 10mg (synthetic thymosin beta 4, 43 residues N-terminally acetylated, C₂₁₂H₃₅₀N₅₆O₇₈S, 4963.4 g/mol, CAS 77591-33-4) and GHK-Cu 50mg (glycyl-L-histidyl-L-lysine copper(II) complex, C₁₄H₂₄CuN₆O₄, 403.9 g/mol, CAS 89030-95-5), co-lyophilised in a single container. Because the components are co-lyophilised, one reconstitution step puts all three into solution at a fixed ratio, and they cannot subsequently be separated or independently varied. The blend itself has not been studied as a combination; the published evidence is three separate single-compound literatures.The blend itself has not been studied as a combination. Each finding cited here comes from work on one component alone.

GLOW Research Applications

• BPC-157 : Hsieh and colleagues (J Mol Med, 2017) linked its angiogenic effect in chick membrane and endothelial tube assays to VEGFR2 activation and up-regulation.
• BPC-157 : in cultured rat tendon fibroblasts it increased migration and FAK and paxillin phosphorylation (Chang et al., J Appl Physiol, 2011).
• TB-500 : the seven amino acid actin-binding motif of thymosin beta 4 matched the whole molecule in endothelial migration assays at about 50 nM (Philp et al., FASEB J, 2003).
• GHK-Cu : raised MMP-2, TIMP-1 and TIMP-2 in dermal fibroblast culture. Copper ions alone reproduced the MMP-2 effect, GHK alone did not (Siméon et al., Life Sci, 2000).

Bock-Marquette and colleagues (Nature, 2004) found thymosin beta 4 forms a complex with PINCH and integrin-linked kinase, activating Akt in cardiac cells. Pickart and colleagues (Nature, 1980) showed GHK readily binds copper(II) and increases copper uptake into cultured hepatoma cells. These findings come from different systems and cannot be added up into a prediction for the blend.

Each component of the GLOW blend has its own preclinical and in-vitro literature, and the blend has none of its own. BPC-157 appears in in-vitro and animal work on angiogenesis and endothelial tube formation, focal adhesion signalling, gastrointestinal mucosal integrity and nitric oxide pathway modulation; Hsieh et al. (J Mol Med, 2017) reported VEGFR2 upregulation and receptor internalisation in human umbilical vein endothelial cells, and Chang et al. (J Appl Physiol, 2011) reported FAK and paxillin phosphorylation with increased outgrowth and migration in cultured rat tendon fibroblasts. A 2025 review by McGuire and colleagues in Current Reviews in Musculoskeletal Medicine found no adequately powered randomised controlled trial. TB-500 is synthetic thymosin beta 4, the principal G-actin sequestering molecule in eukaryotic cells; Philp et al. (FASEB J, 2003) reported that the LKKTETQ actin-binding motif at residues 17 to 23 is sufficient to promote endothelial cell migration in aortic ring and chorioallantoic assays, and Bock-Marquette et al. (Nature, 2004) reported integrin-linked kinase and Akt activation in mouse cardiac models. GHK-Cu is studied as a copper delivery ligand and as a matrikine, the GHK motif occurring within the alpha-2(I) chain of type I collagen; Pickart et al. (Nature, 1980) reported facilitated copper uptake into cultured cells, Siméon et al. (Life Sci, 2000) reported upregulated matrix metalloproteinase-2 alongside its tissue inhibitors in fibroblast culture, and Maquart et al. (J Clin Invest, 1993) reported connective tissue accumulation endpoints in a rat diffusion-chamber model. Because these findings come from different systems at different scales, they cannot be summed into a prediction about the blend, and any design attributing an effect to a single component requires the individual vials.

GLOW vs KLOW vs Individual Vials

KLOW holds the same three components at the same masses plus KPV 10mg, 80mg in total. KPV adds a gut epithelial and PepT1 uptake literature. Individual BPC-157, TB-500 and GHK-Cu vials are the only format that allows a single-compound control, independent concentrations or attribution of an effect to one molecule. Some suppliers sell GLOW as a kit of five or six separate vials; ours is one pre-blended vial.

The three formats differ in composition and in experimental flexibility, not in quality. GLOW is 70mg total: BPC-157 10mg, TB-500 10mg, GHK-Cu 50mg. KLOW is the same three components at the same masses plus KPV 10mg, giving 80mg total, and adds a mechanistically distinct compound whose literature centres on PepT1-mediated uptake and NF-κB signalling in epithelial and colitis models rather than on angiogenesis, actin dynamics or copper transport. Individual BPC-157, TB-500 and GHK-Cu vials cost more in handling steps but are the only format that permits a single-compound control arm, an independent concentration per compound, or attribution of an observed effect to a specific molecule. One further note on the blend formats: because GHK-Cu is 403.9 g/mol against 1419.53 for BPC-157 and 4963.4 for thymosin beta 4, the 50:10:10 mass split is nothing like a 5:1:1 molar ratio, so molar arithmetic must be done component by component. Note also the supply-format difference across the market: GLOW and KLOW are sold by some suppliers as five- and six-vial kits, whereas the material here is a single pre-blended vial taking one reconstitution.

Research Overview

GLOW is a supplier designation for a pre-blended multi-peptide research vial, not a single molecule. The GLOW 70mg vial supplied here contains BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg co-lyophilised in one container. The honest starting point for evaluating any glow peptide product is that the blend has not been studied as a combination: no published in-vitro or in-vivo work has examined these three compounds co-administered at this ratio, and no synergy between them has been demonstrated. What exists is three separate literatures, one per component, and that is what the glow stack peptide format aggregates. BPC-157 is a 15-residue pentadecapeptide, GEPPPGKPADDAGLV, 1419.53 g/mol, corresponding to a partial sequence of Body Protection Compound originally characterised in human gastric juice, and unusual among peptides of this length for resisting hydrolysis at low pH. Hsieh and colleagues (J Mol Med, 2017, PMID 27847966) reported upregulation and internalisation of VEGFR2 in human umbilical vein endothelial cells; Chang and colleagues (J Appl Physiol, 2011, PMID 21030672) reported increased FAK and paxillin phosphorylation in cultured rat tendon fibroblasts. TB-500 is synthetic thymosin beta 4, a 43-residue N-terminally acetylated polypeptide of 4963.4 g/mol and the principal G-actin sequestering molecule in eukaryotic cells. Philp and colleagues (FASEB J, 2003, PMID 14500546) showed the LKKTETQ actin-binding motif at residues 17 to 23 is sufficient to promote endothelial cell migration in aortic ring and chorioallantoic assays, and Bock-Marquette and colleagues (Nature, 2004, PMID 15565145) reported integrin-linked kinase and Akt activation in mouse cardiac models. GHK-Cu, the copper(II) chelate of glycyl-L-histidyl-L-lysine at 403.9 g/mol, is the largest fraction of the glow blend peptide by mass. Pickart and colleagues (Nature, 1980, PMID 7453802) reported facilitated copper uptake into cultured cells, and Siméon and colleagues (Life Sci, 2000, PMID 11045606) reported upregulated MMP-2 alongside its tissue inhibitors in fibroblast culture. One format distinction is worth noting when comparing glow peptides between suppliers: this is a single pre-blended vial taking one reconstitution step, rather than a multi-vial kit reconstituted component by component. Supplied strictly for in-vitro laboratory research use only. No therapeutic, cosmetic or appearance claim is made or implied.

Storage and Reconstitution

Store GLOW powder at -20°C, away from light and moisture, for up to 24 months. After reconstitution, keep the solution at 2-8°C in a light-protected container and use it within 4 weeks. For longer storage, freeze single-use aliquots at -20°C and avoid repeated freeze-thaw cycles.

Light protection matters more for GLOW than for a single-peptide vial, because a copper(II) peptide complex is photolabile and the whole blend must be handled to the standard of its most fragile component. Keep lyophilised vials and reconstituted solution shielded from UV and fluorescent light and use amber or foil-wrapped vessels for aliquots. Freeze-thaw cycling can disrupt the copper coordination sphere as well as degrade the peptide backbones, so single-use aliquots are preferable to repeatedly accessing one stock.

Vials are sold on their own, without bacteriostatic water for mixing or other supplies.

How to reconstitute and handle

Let the vial and the bacteriostatic water reach room temperature and swab both stoppers with alcohol. Add the water slowly down the inside wall of the vial and swirl gently until dissolved. Do not shake or vortex. Expect a blue to blue-violet solution from the Cu(II) in GHK-Cu. A colourless or green-tinged solution suggests the copper complex has broken down. Use glass or good-quality polypropylene labware and avoid long contact with stainless steel.

Two blend-specific points apply. Never shake or vortex, the 43-residue thymosin beta 4 component is shear sensitive and agitation reduces recovery of intact peptide. And the reconstituted solution will not be colourless: expect a blue to blue-violet tint from the d-d transition of the Cu(II) centre in the GHK-Cu component, which is expected and is the standard bench indicator that the copper complex is intact. A colourless or green-tinged solution indicates the complex has been disrupted rather than simply diluted, and visible absorption around 500 to 600 nm is the usual check. Reconstitute away from direct light and use glass or high-grade polypropylene labware, avoiding prolonged contact with stainless steel or other chelating surfaces that can strip Cu(II) from the tripeptide.

• Allow the vial to reach room temperature before opening so condensation does not settle on the lyophilised cake.
• Handle the whole vial according to the most fragile component in it. Because GHK-Cu is a photolabile copper(II) peptide complex, keep the entire blend light-protected throughout storage, reconstitution and aliquoting, and use amber or foil-wrapped vessels for aliquots.
• Use glass or high-grade polypropylene labware and avoid prolonged contact with stainless steel or other chelating surfaces, which can strip Cu(II) from the tripeptide. Strong chelators, phosphate-rich buffers and reducing agents in an experimental medium will compete for the copper centre and alter the species actually present.
• Expect the reconstituted solution to carry a blue to blue-violet tint contributed by the Cu(II) centre of the GHK-Cu component. Visible absorption in the 500 to 600 nm region is the standard bench check on copper complex integrity, and a colourless solution indicates the complex has been disrupted rather than simply diluted.
• Freeze-thaw cycling degrades peptide backbones and can additionally disrupt the copper coordination sphere.
• The three components cannot be separated once dissolved. Any experiment requiring a single-compound control, an independent concentration per compound, or component-level attribution of an observed effect must use the individual BPC-157, TB-500 and GHK-Cu vials instead.

For the full method, see the peptide reconstitution guide and the reconstitution calculator.

Research References

• Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017)
• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival and cell migration (Chang et al., J Appl Physiol, 2011)
• The actin binding site on thymosin beta4 promotes angiogenesis (Philp et al., FASEB J, 2003)
• Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Bock-Marquette et al., Nature, 2004)
• Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells (Pickart et al., Nature, 1980)
• The tripeptide-copper complex GHK-Cu stimulates matrix metalloproteinase-2 expression by fibroblast cultures (Siméon et al., Life Sci, 2000)
• Growth-modulating plasma tripeptide GHK may function by facilitating copper uptake into cells (Pickart et al., Nature, 1980)

Published research on GLOW is indexed on PubMed. See our full UK buyer's guide for GLOW.